These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 23178294)
1. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Vincent FB; Morand EF; Murphy K; Mackay F; Mariette X; Marcelli C Ann Rheum Dis; 2013 Feb; 72(2):165-78. PubMed ID: 23178294 [TBL] [Abstract][Full Text] [Related]
2. Antidrug antibodies to tumour necrosis factor specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective; comment on the article by Vincent et al. den Broeder AA; van der Maas A; van den Bemt BJ Ann Rheum Dis; 2013 Jul; 72(7):e14. PubMed ID: 23585517 [No Abstract] [Full Text] [Related]
3. Personalized medicine: theranostics (therapeutics diagnostics) essential for rational use of tumor necrosis factor-alpha antagonists. Bendtzen K Discov Med; 2013 Apr; 15(83):201-11. PubMed ID: 23636137 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of anti-tumour necrosis factor drugs in rheumatic diseases. Spinelli FR; Valesini G Clin Exp Rheumatol; 2013; 31(6):954-63. PubMed ID: 23981925 [TBL] [Abstract][Full Text] [Related]
5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Hyrich KL; Watson KD; Silman AJ; Symmons DP; Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046 [TBL] [Abstract][Full Text] [Related]
6. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Bendtzen K; Ainsworth M; Steenholdt C; Thomsen OØ; Brynskov J Scand J Gastroenterol; 2009; 44(7):774-81. PubMed ID: 19140087 [TBL] [Abstract][Full Text] [Related]
7. Efficacy in current practice of switching between anti-tumour necrosis factor- α agents in spondyloarthropathies. Paccou J; Solau-Gervais E; Houvenagel E; Salleron J; Luraschi H; Philippe P; Duquesnoy B; Flipo RM Rheumatology (Oxford); 2011 Apr; 50(4):714-20. PubMed ID: 21131271 [TBL] [Abstract][Full Text] [Related]
8. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090 [TBL] [Abstract][Full Text] [Related]
9. Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine. Gehin JE; Goll GL; Brun MK; Jani M; Bolstad N; Syversen SW BioDrugs; 2022 Nov; 36(6):731-748. PubMed ID: 36315391 [TBL] [Abstract][Full Text] [Related]
11. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559 [TBL] [Abstract][Full Text] [Related]
12. Predictors of response to TNF inhibitors in rheumatoid arthritis - do we have new tools for personalized medicine? Simsek I Bull NYU Hosp Jt Dis; 2012; 70(3):187-90. PubMed ID: 23259626 [TBL] [Abstract][Full Text] [Related]
13. Assays and strategies for immunogenicity assessment of biological agents. Nencini F; Pratesi S; Petroni G; Matucci A; Maggi E; Vultaggio A Drug Dev Res; 2014 Nov; 75 Suppl 1():S4-6. PubMed ID: 25381974 [TBL] [Abstract][Full Text] [Related]
14. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C; Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098 [TBL] [Abstract][Full Text] [Related]
16. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up. Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496 [TBL] [Abstract][Full Text] [Related]
17. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome. Jit M; Henderson B; Stevens M; Seymour RM Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509 [TBL] [Abstract][Full Text] [Related]
18. [Paradigm shift in the treatment of rheumatoid arthritis by biologics]. Tanaka Y Rinsho Byori; 2008 Apr; 56(4):309-15. PubMed ID: 18516965 [TBL] [Abstract][Full Text] [Related]
19. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Solau-Gervais E; Laxenaire N; Cortet B; Dubucquoi S; Duquesnoy B; Flipo RM Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526 [TBL] [Abstract][Full Text] [Related]